The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables

Por Lind, Marcus, Odén, Anders, Fahlén, Martin, Eliasson, Björn
Publicado em 2009

Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone

Por Håkansson, Joakim, Eliasson, Björn, Smith, Ulf, Enerbäck, Sven
Publicado em 2011

Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients

Por Kiadaliri, Aliasghar A., Eliasson, Björn, Gerdtham, Ulf-G
Publicado no Health Qual Life Outcomes (2015)

Metabolic predictors of impaired glucose tolerance and type 2 diabetes in a predisposed population – A prospective cohort study

Por Henninger, Josefin, Hammarstedt, Ann, Rawshani, Araz, Eliasson, Björn
Publicado no BMC Endocr Disord (2015)

The role of chloramines in treatment of diabetic foot ulcers: an exploratory multicentre randomised controlled trial

Por Bergqvist, Karin, Almhöjd, Ulrica, Herrmann, Irene, Eliasson, Björn
Publicado no Clin Diabetes Endocrinol (2016)

Metabolic characteristics of individuals at a high risk of type 2 diabetes – a comparative cross-sectional study

Por Henninger, Josefin, Rawshani, Araz, Hammarstedt, Ann, Eliasson, Björn
Publicado no BMC Endocr Disord (2017)

Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study

Por Svensson, Ann-Marie, Miftaraj, Mervete, Franzén, Stefan, Eliasson, Björn
Publicado no Clin Diabetes Endocrinol (2017)

Cephalic phase of insulin secretion in response to a meal is unrelated to family history of type 2 diabetes

Por Eliasson, Björn, Rawshani, Araz, Axelsen, Mette, Hammarstedt, Ann, Smith, Ulf
Publicado no PLoS One (2017)

The size of large adipose cells is a predictor of insulin resistance in first-degree relatives of type 2 diabetics

Por Yang, Jian, Eliasson, Bjorn, Smith, Ulf, Cushman, Samuel W., Sherman, Arthur
Publicado em 2012

Adipocyte Hypertrophy, Inflammation and Fibrosis Characterize Subcutaneous Adipose Tissue of Healthy, Non-Obese Subjects Predisposed to Type 2 Diabetes

Por Henninger, A. M. Josefin, Eliasson, Björn, Jenndahl, Lachmi E., Hammarstedt, Ann
Publicado em 2014

Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type...

Por Kiadaliri, Aliasghar A., Gerdtham, Ulf G., Eliasson, Bjorn, Carlsson, Katarina Steen
Publicado no Diabetes Ther (2014)

Clinical Effects and Safety of Direct-Acting Insulin Analogs in Patients with Type 1 Diabetes: A Nation-Wide Observational Cohort Study

Por Lak, Vincent, Svensson, Ann-Marie, Miftaraj, Mervete, Franzén, Stefan, Eliasson, Björn
Publicado no Diabetes Ther (2016)

Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice

Por Svensson, Ann-Marie, Lak, Vincent, Fard, MirNabi Pirouzi, Eliasson, Björn
Publicado no Clin Diabetes Endocrinol (2015)

Impact of ethnicity on progress of glycaemic control in 131 935 newly diagnosed patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes R...

Por Rawshani, Araz, Svensson, Ann-Marie, Rosengren, Annika, Zethelius, Björn, Eliasson, Björn, Gudbjörnsdottir, Soffia
Publicado no BMJ Open (2015)

Amelioration of insulin resistance by rosiglitazone is associated with increased adipose cell size in obese type 2 diabetic patients

Por Eliasson, Bjorn, Smith, Ulf, Mullen, Shawn, Cushman, Samuel W, Sherman, Arthur S, Yang, Jian
Publicado no Adipocyte (2014)

Risk Prediction of Cardiovascular Disease in Type 2 Diabetes: A risk equation from the Swedish National Diabetes Register

Por Cederholm, Jan, Eeg-Olofsson, Katarina, Eliasson, Björn, Zethelius, Björn, Nilsson, Peter M., Gudbjörnsdottir, Soffia
Publicado em 2008

Clinical Usefulness of Different Lipid Measures for Prediction of Coronary Heart Disease in Type 2 Diabetes: A report from the Swedish National Diabetes Register

Por Eliasson, Björn, Cederholm, Jan, Eeg-Olofsson, Katarina, Svensson, Anne-Marie, Zethelius, Björn, Gudbjörnsdottir, Soffia
Publicado em 2011

HbA1C and Cancer Risk in Patients with Type 2 Diabetes – A Nationwide Population-Based Prospective Cohort Study in Sweden

Por Miao Jonasson, Junmei, Cederholm, Jan, Eliasson, Björn, Zethelius, Björn, Eeg-Olofsson, Katarina, Gudbjörnsdottir, Soffia
Publicado em 2012

Increased Urine IgM and IgG(2) Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes

Por Torffvit, Ole, Kalani, Majid, Apelqvist, Jan, Eliasson, Björn, Eriksson, Jan W., Brismar, Kerstin, Jörneskog, Gun
Publicado em 2012

Towards Renewed Health Economic Simulation of Type 2 Diabetes: Risk Equations for First and Second Cardiovascular Events from Swedish Register Data

Por Ahmad Kiadaliri, Aliasghar, Gerdtham, Ulf-G., Nilsson, Peter, Eliasson, Björn, Gudbjörnsdottir, Soffia, Carlsson, Katarina Steen
Publicado em 2013